NeuroBlu Analytics v4.26 delivers the largest data expansion in the platform's history. The 26R1 dataset grows NeuroBlu to 41M+ patients, adds six clinical scales across new therapeutic areas, and puts Symptom Intelligence into production for the first time.

This release adds therapeutic area coverage in alcohol use disorders, migraine, and Parkinson's disease. It expands access to clinical assessments, launches two new production features (Symptom Lookup and Person Summary), and introduces a structured way to explore symptom data across sources.

‍

6 New Clinical Scales Added, with Continued Growth Across Existing Measures

This release introduces six new clinical scales, broadening access to key standardized assessments. Newly available measures include:

• AUDIT (Alcohol Use Disorders Identification Test)
• CAGE and CAGE-AID (alcohol and substance use screening)
• CIWA-Ar (withdrawal severity)
• MIDAS (migraine disability)
• TUG (mobility evaluation)

We’ve also continued to strengthen our most widely used scales, which now represent significant data volume:

• PHQ-9 (9.7M+)
• GAD-7 (3.9M+)
• AUDIT-C (2.1M+)
• C-SSRS (2.0M+)

‍

Expanding Into New Therapeutic Areas with Growing Patient Coverage

This release expands our footprint into new therapeutic areas such as AUD, migraine, and Parkinson’s disease, enabling deeper exploration across both neurological and behavioral health domains.

We’re also increasing patient coverage across key conditions, including:

• Alzheimer’s disease (446K)
• Mild cognitive impairment (381K)
• Parkinson’s disease (277K)
• Epilepsy (728K)
• Multiple sclerosis (~146K)
• Migraine (2.5M)

Our behavioral health dataset also continues to expand, now including:

• Major depressive disorder (11.7M+)
• Substance use disorder (9.9M+)
• Generalized anxiety disorder (6.5M+)
• Attention deficit hyperactivity disorder (5.1M+)
• Post-traumatic stress disorder (2.2M+)
• Bipolar I disorder (514K+)
• Bipolar II disorder (457K+)
• Schizoaffective disorder (393K+)
• Schizophrenia (493K+)

‍

Symptom Lookup and Person Summary: New Production Features

Two new production features ship with this release:

Symptom Lookup (symptom_lookup) is the first piece of the Symptom Intelligence Framework. It provides a structured view of symptom data across structured, semi-structured, and unstructured sources, with standardized symptom-to-observation mappings for cross-partner analysis. Replaces observation_symptom_grouping_lookup (deprecated in 26R2).

Person Summary (person_summary) replaces master_person_stats with a streamlined warehouse table for person-level statistics. Available alongside master_person_stats in 26R1, deprecated in 26R2.

‍

Platform Updates

• Brand Dashboards: Expanded from 36 drugs to disease-context views with competitive landscape and treatment pattern analysis
• NeuroBlu Analytics Reports: Landing page with explainer available. Full production launch targeted next quarter.
• Documentation: Data Overview refreshed for 26R1, labs and medication best practices guide added

‍

‍

NeuroBlu now covers 41M+ patients across five active data partners with 6 new clinical scales and two production features. Alcohol use disorders, migraine, and Parkinson's disease are researchable for the first time. Symptom Intelligence is live.

Next quarter: NeuroBlu Reports moves to production, and the Intelligence Layer deepens with automated reporting and cross-source symptom analysis.

Interested in seeing NeuroBlu Analytics for yourself? Contact us to schedule a demo.

Already a customer? Log in here.

‍